

# Lori A Wood

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10300400/publications.pdf>

Version: 2024-02-01

31  
papers

1,009  
citations

623734

14  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1476  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	1.9	382
2	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	1.9	78
3	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	1.9	71
4	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017, 71, 204-209.	1.9	65
5	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016, 65, 102-108.	2.8	60
6	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018, 124, 3677-3683.	4.1	53
7	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	1.9	41
8	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 902-909.	2.8	37
9	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	5.4	31
10	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4507-4507.	1.6	28
11	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 115-125.	2.8	22
12	Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 799.e1-799.e10.	1.6	18
13	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	5.4	17
14	Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. <i>Canadian Urological Association Journal</i> , 2019, 14, E154-E158.	0.6	15
15	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	1.9	14
16	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. <i>Canadian Urological Association Journal</i> , 2020, 14, E499-E506.	0.6	13
17	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , 2017, 71, 970-978.	1.9	12
18	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.6	10
20	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	5.9	10
21	Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. European Urology Focus, 2022, 8, 1703-1710.	3.1	5
22	Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 2020, 14, E537-E542.	0.6	4
23	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 210-218.	1.9	4
24	Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis. Current Oncology, 2022, 29, 1808-1812.	2.2	3
25	Followup imaging studies in metastatic castration-resistant prostate cancer: An individualized approach. Canadian Urological Association Journal, 2018, 13, 201-202.	0.6	2
26	Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum. Canadian Urological Association Journal, 2012, 1, S6-S12.	0.6	1
27	Accuracy of kidney cancer diagnosis and histological subtype within Canadian cancer registry data. Canadian Urological Association Journal, 2017, 11, E326-9.	0.6	1
28	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association Journal, 2020, 15, 132-137.	0.6	1
29	Renal cell carcinoma: currently the most interesting genitourinary malignancy. Canadian Urological Association Journal, 2012, 1, S74-6.	0.6	0
30	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of Cancer Education, 2019, 34, 14-18.	1.3	0
31	A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association Journal, 2020, 14, 346-351.	0.6	0